ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2017
Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC).
Open access · bronzeAbstract read
In one paragraph
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.Blood advances · 2026Article
- Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.EClinicalMedicine · 2026Article
- Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.Current obesity reports · 2025Review
- Global, regional, and national burden of multiple myeloma, 1990 to 2021 and predictions to 2035: an analysis of the Global Burden of Disease Study 2021.Frontiers in medicine · 2025Article
- Global, regional, and national burden of multiple myeloma from 1990 to 2021 and projections for 2040: a systematic analysis for the global burden of disease 2021 study.Frontiers in epidemiology · 2025Article
- Article
- Body size and risk of multiple myeloma in the Black Women's Health Study.British journal of cancer · 2024Article
- Benefits of Mediterranean and Japanese Diets among Nurses: A Scoping Literature Review.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Addressing the disparities: the approach to the African American patient with multiple myeloma.Blood cancer journal · 2023Review
- Geospatial analysis of population-based incidence of multiple myeloma in the United States.Cancer epidemiology · 2023Article
- Review
- Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?Advances in hematology · 2021Review
- Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities.Blood cancer journal · 2020Article
- Dissecting racial disparities in multiple myeloma.Blood cancer journal · 2020Review
- Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes.Frontiers in oncology · 2020Article
- Elucidating Under-Studied Aspects of the Link Between Obesity and Multiple Myeloma: Weight Pattern, Body Shape Trajectory, and Body Fat Distribution.JNCI cancer spectrum · 2019Article
- Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies.JNCI cancer spectrum · 2019Article
- Antitumor Activity of Asiaticoside Against Multiple Myeloma Drug-Resistant Cancer Cells Is Mediated by Autophagy Induction, Activation of Effector Caspases, and Inhibition of Cell Migration, Invasion, and STAT-3 Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.International journal of molecular sciences · 2018Review
- Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts.British journal of cancer · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 1 institution in 1 country.
Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. brenda.birmann@channing.harvard.edu.
Gabriella AndreottiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, Maryland.
Anneclaire J De RoosDepartment of Environmental and Occupational Health, Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania.
Nicola J CampDivision of Hematology and Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, Utah.
Brian C H ChiuDepartment of Health Studies, University of Chicago, Chicago, Illinois.
John J SpinelliCancer Control Research, BC Cancer Agency and School of Population and Public Health, University of British Columbia, Vancouver, British Coulmbia, Canada.
Nikolaus BeckerGerman Cancer Center, Division of Cancer Epidemiology, Heidelberg, Germany.
Véronique Benhaim-LuzonInternational Agency for Research on Cancer, Lyon, France.
Parveen BhattiProgram in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Paolo BoffettaMount Sinai School of Medicine, New York, New York.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Elizabeth E BrownDepartment of Pathology and the Cancer Control and Population Sciences Program, UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.
Pierluigi CoccoDepartment of Public Health, Occupational Health Section, University of Cagliari, Cagliari, Italy.
Laura CostasUnit of Infections and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.
Wendy CozenDepartment of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Silvia de SanjoséUnit of Infections and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.
Lenka ForetováDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.
Marc MaynadiéRegistry of Hematological malignancies of Côte d'Or, University of Burgundy, and University Hospital, Dijon, France.
Kirsten MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Alexandra NietersCenter for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Anthony StainesIreland School of Nursing and Human Sciences, Dublin City University, Glasnevin, Dublin, Ireland.
Guido TricotDepartment of Internal Medicine, University of Iowa, Iowa City, Iowa.
Dennis WeisenburgerDepartment of Pathology, City of Hope, Duarte, California.
Yawei ZhangDepartment of Surgery, Yale School of Medicine, New Haven, Connecticut.
Dalsu BarisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, Maryland.
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, Maryland.
Centre International de Recherche sur le Cancer · FR
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0MA prospective analysis of peripheral blood cytokines and non-Hodgkin lymphomaR01CA149445 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M · 2011 to 2015
$3.0MProspective evaluation of IGF and IL-6 Dysregulation and Multiple MyelomaR01CA127435 · NCI · WASHINGTON UNIVERSITY · PI COLDITZ, GRAHAM A. · 2007 to 2010
$1.4MEnergy Balance, IGF Dysregulation and Multiple MyelomaK07CA115687 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M · 2006 to 2010
$796kDiet patterns, aspirin use, obesity and multiple myeloma: a prospective analysisR21CA198239 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M · 2015 to 2016
$454kBeyond GWAS: the next 10 years of InterLymphR13CA159842 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COZEN, WENDY · 2011 to 2011
$12kNCI NIH HHS K07 CA115687NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA127435NCI NIH HHS R01 CA149445NCI NIH HHS R13 CA159842NCI NIH HHS R21 CA198239World Health Organization 001
Abstract
PubMed holds no abstract for this paper.
Indexed as
Body Mass IndexAdultAgedAnthropometryCase-Control StudiesFemaleHumansMaleMiddle AgedMultiple MyelomaRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.